Trial Profile

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jun 2026 According to a Nura Bio media release, company announced the completion of a $73.8M Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs. The financing, led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures, will fund the development of Nura Bios clinical pipeline, including the Phase 1b/2a study of NB-4746 which recently commenced dosing in ALS patients.
22 Jun 2026 According to a Nura Bio media release, first patient has been dosed in this Phase 1b/2a ALS study with NB-4746.
15 May 2026 Planned End Date changed from 1 Dec 2027 to 1 Feb 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com